Influence of a terminal period of fasting on the serum and tissue lipid effects of ethyl chlorophenoxyisobutyrate (CPIB).
D000818:Animals; D000963:Antimetabolites / Q000494:pharmacology*; D002087:Butyrates / Q000494:pharmacology*; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D005215:Fasting; D000960:Hypolipidemic Agents / Q000494:pharmacology; D050356:Lipid Metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D010743:Phospholipids / Q000097:blood / Q000378:metabolism; D051381:Rats; D014280:Triglycerides / Q000097:blood / Q000378:metabolism
D000963:Antimetabolites; D002087:Butyrates; D000960:Hypolipidemic Agents; D010743:Phospholipids; D014280:Triglycerides; D002784:Cholesterol